This is an open‐label, prospective, single‐center, single‐arm, exploratory clinical trial to observe and evaluate the efficacy and safety of continued apatinib combined with EGFR‐TKI in NSCLC patients with slow progression after EGFR‐TKI monotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.